PT Prodia Diagnostic Line Tbk (IDX:PRDL)

Revenue by Segment

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Clinical Chemistry	60.38B	50.59B	93.99B
Clinical Chemistry Growth	19.35%	-46.17%	-
Hematology	4.09B	1.06B	93.03M
Hematology Growth	284.57%	1041.98%	-
Instrument	8.83B	6.89B	16.53B
Instrument Growth	28.05%	-58.31%	-
Immunology & Biomoleculer	56.57M	25.59M	962.88M
Immunology & Biomoleculer Growth	121.04%	-97.34%	-
Services	1.02B	83.30M	202.00M
Services Growth	1127.47%	-58.76%	-
Total	74.37B	58.66B	111.78B
Total Growth	26.79%	-47.52%	-

Revenue by Geography

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Indonesia	74.37B	58.66B	111.78B
Indonesia Growth	26.79%	-47.52%	-
Total	74.37B	58.66B	111.78B
Total Growth	26.79%	-47.52%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 14, 2026

Data Sources Report a data error